Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin
the ONA take:
According to a new study published in the journal The Lancet, researchers have found that children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
For the 10-year trial, researchers followed 583 pediatric patients with stage II or III Wilm's tumor who were at intermediate risk for disease relapse. Results demonstrated that 96.5% of patients whose treatment regimen contained doxorubicin survived for 5 or more years versus 95.8% of those who did not receive the cardiotoxic drug. Researchers found that those who did not receive doxorubicin and relapsed could be successfully re-treated.
"Thanks to the results of this trial fewer children with this disease will have to have treatment that could cause them lifelong side effects without much benefit," lead author Professor Kathy Pritchard-Jones, a researcher at the Institute of Child Health, University College London and consultant oncologist at Great Ormond Street Hospital in London said.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|